Angion Biomedica Corp - ESG Rating & Company Profile powered by AI
This webpage includes a Q&A table for Angion Biomedica Corp. Detailed ESG assessment of Angion Biomedica Corp can be accessed by signing up for free. The ESG rating for Angion Biomedica Corp represents the company's reporting of the UN Sustainable Development Goals.
Angion Biomedica Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.3; made up of an environmental score of 1.6, social score of 3.2 and governance score of 8.0.
4.3
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1284 | Sinopep Allsino Bio Pharmaceutical Co Ltd | 4.4 | High |
| 1284 | Vanda Pharmaceuticals Inc | 4.4 | High |
| 1335 | Angion Biomedica Corp | 4.3 | High |
| 1335 | AddLife AB | 4.3 | High |
| 1335 | Agenus Inc | 4.3 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Angion Biomedica Corp have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Angion Biomedica Corp disclose current and historical energy intensity?
Sign up for free to unlockDoes Angion Biomedica Corp report the average age of the workforce?
Sign up for free to unlockDoes Angion Biomedica Corp reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Angion Biomedica Corp disclose its ethnicity pay gap?
Sign up for free to unlockDoes Angion Biomedica Corp disclose cybersecurity risks?
Sign up for free to unlockDoes Angion Biomedica Corp offer flexible work?
Sign up for free to unlockDoes Angion Biomedica Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Angion Biomedica Corp disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Angion Biomedica Corp conduct supply chain audits?
Sign up for free to unlockDoes Angion Biomedica Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Angion Biomedica Corp conduct 360 degree staff reviews?
Sign up for free to unlockDoes Angion Biomedica Corp disclose the individual responsible for D&I?
Sign up for free to unlockDoes Angion Biomedica Corp disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Angion Biomedica Corp disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Angion Biomedica Corp disclose water use targets?
Sign up for free to unlockDoes Angion Biomedica Corp have careers partnerships with academic institutions?
Sign up for free to unlockDid Angion Biomedica Corp have a product recall in the last two years?
Sign up for free to unlockDoes Angion Biomedica Corp disclose incidents of discrimination?
Sign up for free to unlockDoes Angion Biomedica Corp allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Angion Biomedica Corp issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Angion Biomedica Corp disclose parental leave metrics?
Sign up for free to unlockDoes Angion Biomedica Corp disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Angion Biomedica Corp disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Angion Biomedica Corp disclose the pay ratio of women to men?
Sign up for free to unlockDoes Angion Biomedica Corp support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Angion Biomedica Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Angion Biomedica Corp reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Angion Biomedica Corp involved in embryonic stem cell research?
Sign up for free to unlockDoes Angion Biomedica Corp disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Angion Biomedica Corp disclose its waste policy?
Sign up for free to unlockDoes Angion Biomedica Corp report according to TCFD requirements?
Sign up for free to unlockDoes Angion Biomedica Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Angion Biomedica Corp disclose energy use targets?
Sign up for free to unlockDoes Angion Biomedica Corp disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Angion Biomedica Corp have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Angion Biomedica Corp
These potential risks are based on the size, segment and geographies of the company.
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.